anti-PTK7 CAR-T

**anti-PTK7 CAR-T** is an investigational **PTK7-directed CAR-T cell therapy** in which autologous or allogeneic T cells are genetically engineered to express a chimeric antigen receptor recognizing **protein tyrosine kinase 7** on tumor cells. The construct described across preclinical reports typically uses an anti-PTK7 scFv linked to intracellular signaling domains such as **4-1BB or CD28** and **CD3 zeta** to activate cytotoxic T-cell killing after PTK7 binding. The program remains **preclinical** and has been explored by multiple academic and industry groups, including work associated with **CRISPR Therapeutics** on genome-edited allogeneic anti-PTK7 CAR-T cells, with reported antitumor activity in xenograft models of solid tumors and neuroblastoma. PTK7 is pursued because it is overexpressed across several malignancies, but potential **on-target off-tumor toxicity** remains an important translational consideration.

Other names

PTK7-targeted CAR-T cellsPTK-7-targeted CAR-T cellsPTK 7-targeted CAR-T cellsanti-PTK7 chimeric antigen receptor T cellsanti-PTK-7 chimeric antigen receptor T cellsanti-PTK 7 chimeric antigen receptor T cellsPTK7 CAR-TPTK-7 CAR-TPTK 7 CAR-T